Breaking News

QHP Capital Acquires Applied StemCell

ASC’s platform of GMP-grade allogeneic iPSC and TARGATT gene editing technology provides shorter manufacturing timelines.

QHP Capital acquired Applied StemCell, Inc., a cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry in developing and manufacturing cell and gene products. ASC offers comprehensive and customized cell and gene CRO/CDMO solutions. Its platform of GMP-grade allogeneic induced pluripotent stem cells (iPSC) and its  TARGATT gene editing technology provide shorter manufacturing timelines, non-viral gene editing, and genomic stability and safety. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters